SEC Filing Summary: GSK Plc Form 6-K
Business Context and Reporting Period
This Form 6-K was filed by GlaxoSmithKline plc on January 14, 2020, for the month of January 2020. The filing serves as a transaction notification regarding a Person Discharging Managerial Responsibilities (PDMR) and does not contain periodic financial results or operational updates.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is strictly a regulatory disclosure of a specific securities transaction and excludes consolidated financial statements.
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document details a single transaction involving the acquisition of American Depositary Shares (ADSs) by a senior executive.
Transaction Details and Commentary
- Executive: Mr. B McNamara, CEO of GSK Consumer Healthcare.
- Transaction Type: Acquisition of ADSs via dividend reinvestment under the Deferred Annual Bonus Plan Post-Tax.
- Instrument: American Depositary Shares (ISIN: US37733W1053).
- Date: January 10, 2020.
- Volume: 24.753 ADSs.
- Price: $47.0819 per ADS.
- Exchange: New York Stock Exchange (XNYS).
Management commentary, guidance, outlook, risks, and contingencies are not addressed in this filing.
Investor Verification Points
- Verify the total holdings of Mr. B McNamara following this acquisition to assess alignment with company performance.
- Confirm the terms of the Deferred Annual Bonus Plan Post-Tax to understand the mechanics of the dividend reinvestment.
- Review the company's most recent Form 20-F for comprehensive financial metrics, as this Form 6-K contains no financial data.